Janina Krupińska

Learn More
BACKGROUND Different forms of interferon alpha (IFN-α) have been used for several years in the treatment of chronic viral hepatitis type C (CVHC). Currently, pegylated forms of interferon alpha (PegIFN-α) in combination with ribavirin is the standard treatment. During therapy with IFN-α, side-effects occur, including thyroid diseases. The aim of this study(More)
Nonachlazin diminishes aseptic inflammation provoked by subplantar administration of carrageenin to rats. Nonachlazin increases the sensitivity pain threshold of the rat paw affected by carrageenin-induced inflammation, decreases the reaction of mice to intraperitoneal injection of phenylchinoin, and the ability of the rabbit central nervous system for(More)
UNLABELLED BACKGROUND Considerable progress was made by the introduction of interferon to the treatment of chronic hepatitis C virus infection. This treatment, however, is associated with the risk of developing or exacerbating autoimmune diseases, with chronic autoimmune thyroiditis being one of them. The aim of our study was to evaluate the(More)
  • 1